Alpha Cognition Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-30$6.60 RISE2026-03-27$5.08 PEAK2026-04-22$6.99 113d | -23.0% 87d | Missed | Missed | — | — | +37.6% 26d | Missed |
DROP2025-10-08$7.72 RISE2026-02-05$4.50 PEAK2026-04-22$6.99 196d | -41.7% 120d | Missed | Missed | — | — | +55.3% 76d | Missed |
DROP2025-08-13$9.99 RISE2025-12-15$5.01 PEAK2025-12-30$6.60 139d | -49.8% 124d | Missed | Missed | — | — | +31.7% 15d | Missed |
DROP2025-07-07$11.24 RISE2025-09-30$6.51 PEAK2025-10-08$7.72 93d | -42.1% 85d | Missed | Missed | — | — | +18.6% 8d | Missed |
DROP2025-07-07$11.24 RISE2025-08-25$7.73 PEAK2025-09-12$9.80 67d | -31.3% 49d | Missed | Missed | — | — | +26.9% 18d | Missed |
DROP2024-11-27$6.67 RISE2025-04-08$3.75 PEAK2025-07-07$11.24 222d | -43.8% 132d | Missed | Missed | — | — | +199.7% 90d | Missed |
DROP2024-11-27$6.67 RISE2024-12-16$4.79 PEAK2025-01-28$6.61 62d | -28.2% 19d | Missed | Missed | — | — | +38.0% 43d | Missed |
Maxim Group analyst Naz Rahman initiates coverage on Alpha Cognition (NASDAQ:ACOG) with a Buy rating and announces Price Target of $12.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Alpha Cognition (NASDAQ:ACOG) with a Buy and maintains $18 price target.
Seasoned biotech CFO brings 20+ years of public company finance leadership and IPO experience to support Genvor’s dual-market growth strategyWoodland, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health, today announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financ
Last week saw the newest first-quarter earnings release from Alpha Cognition Inc. ( NASDAQ:ACOG ), an important...
Last week saw the newest first-quarter earnings release from Alpha Cognition Inc. ( NASDAQ:ACOG ), an important...
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsHenry Du - VP of Finance & Accounting and Interim...
Moby summary of Alpha Cognition Inc. Common Stock's Q1 2026 earnings call
Moby summary of Alpha Cognition Inc. Common Stock's Q1 2026 earnings call
Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across prescribers and long-term care facilities. Chief Executive Officer Michael McFadden said the quart
Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across prescribers and long-term care facilities. Chief Executive Officer Michael McFadden said the quart
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of +8.64% and +4.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of +8.64% and +4.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alpha Cognition Q1 2026 revenue hit $3.5M, meeting estimates. Commercial execution accelerated with 40% sequential ZUNVEYL growth and strong prescriber adoption.
VANCOUVER, British Columbia & GRAPEVINE, Texas, May 14, 2026--Alpha Cognition Inc. (ACOG: NASDAQ) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Alpha Cognition Inc:Alpha Cognition Inc. reports first quarter 2026 financial results and provides operational updateAlpha Cognition Inc - Q1 2026 net loss per share $0.32...
Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.39) by 17.95 percent. This is a 146.15 percent decrease over losses of $(0.13) per share from
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACOG | +4.03% | +6.72% | -4.77% | -33.65% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.06% | +12.44% | -1.33% | -46.34% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 15.9K | $87.21K | 0.00% | Trimmed-72.4% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 70,577 | $5.90 | +$416.4K |
| 2026-05-29 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 2,000 | $5.83 | +$11.7K |
| 2026-05-29 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 1,161 | $5.73 | +$6.7K |
| 2026-05-22 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 15,945 | $5.70 | +$90.9K |
| 2026-05-22 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 8,431 | $5.89 | +$49.7K |
| 2026-05-19 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 17,395 | $5.69 | +$99.0K |
| 2026-05-19 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 16,648 | $5.83 | +$97.0K |
| 2026-05-19 | D'Angelo Lauren | Chief Operating Officer | P Open-market purchase | 3,500 | $5.76 | +$20.2K |
| 2026-04-17 | Sensenig Bethany | Director | A Grant / award(deriv) | 6,991 | — | +$0 |
| 2026-04-17 | Sensenig Bethany | Director | A Grant / award | 5,489 | — | +$0 |
| 2026-03-31 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 1,850 | $4.99 | +$9.2K |
| 2026-03-31 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 10,000 | $5.08 | +$50.8K |
| 2026-03-26 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 7,319 | $5.28 | +$38.7K |
| 2026-03-26 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 8,581 | $5.43 | +$46.6K |
| 2026-03-26 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 4,182 | $5.59 | +$23.4K |
| 2026-03-20 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 2,094 | $5.71 | +$12.0K |
| 2026-03-20 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 2,481 | $5.75 | +$14.3K |
| 2026-03-18 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 1,331 | $5.78 | +$7.7K |
| 2026-03-13 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 7,358 | $5.75 | +$42.3K |
| 2026-03-13 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 5,708 | $5.85 | +$33.4K |
| 2026-03-10 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 2,179 | $5.85 | +$12.7K |
| 2026-03-10 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 1,900 | $5.80 | +$11.0K |
| 2026-03-06 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 5,000 | $5.80 | +$29.0K |
| 2026-03-06 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 42,023 | $5.80 | +$243.6K |
| 2026-03-06 | Opaleye Management Inc. | 10% Owner | P Open-market purchase | 19,795 | $5.81 | +$115.0K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.41 | — | — |
| 2026-05-14 | -0.39 | -0.32 | +18.99% |
| 2026-03-26 | -0.27 | -0.31 | -14.81% |
| 2025-11-13 | -0.43 | -0.30 | +30.23% |
| 2025-08-14 | -0.46 | -0.65 | -41.30% |
| 2025-05-15 | -0.78 | -0.13 | +83.33% |
| 2025-03-31 | -0.48 | -0.51 | -6.25% |
| 2024-11-15 | -1.00 | -0.31 | +69.00% |
| 2024-08-12 | -1.00 | -0.25 | +75.00% |
| 2023-03-08 | -0.75 | -1.25 | -66.67% |
| 2022-11-28 | -1.25 | -1.00 | +20.00% |
| 2022-08-25 | -1.25 | -1.25 | — |
| 2022-04-28 | -1.50 | -1.75 | -16.67% |